Dr. Deborah Brown, M.D

Pediatrics Houston, TX Female
NPI: 1083658009
Total Payments
$46,011
2024 Payments
$6,230
Companies
7
Transactions
28

Payment Breakdown by Category

Research$45,638 (99.2%)
Food & Beverage$372.92 (0.8%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $45,638 19 99.2%
Food and Beverage $372.92 9 0.8%

Payments by Type

Research
$45,638
19 transactions
General
$372.92
9 transactions

Top Paying Companies

Company Total Records Latest Year
Takeda Pharmaceuticals U.S.A., Inc. $30,805 9 $0 (2024)
Shire North American Group Inc $14,833 10 $0 (2019)
Novartis Pharmaceuticals Corporation $111.47 5 $0 (2020)
GENZYME CORPORATION $110.44 1 $0 (2024)
Octapharma USA, Inc. $83.50 1 $0 (2019)
Alexion Pharmaceuticals, Inc. $48.00 1 $0 (2019)
Boston Scientific Corporation $19.51 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $6,230 4 Takeda Pharmaceuticals U.S.A., Inc. ($6,100)
2023 $3,050 1 Takeda Pharmaceuticals U.S.A., Inc. ($3,050)
2021 $5,795 2 Takeda Pharmaceuticals U.S.A., Inc. ($5,795)
2020 $15,881 5 Takeda Pharmaceuticals U.S.A., Inc. ($15,860)
2019 $7,771 13 Shire North American Group Inc ($7,548)
2018 $7,285 3 Shire North American Group Inc ($7,285)

All Payment Transactions

28 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
11/20/2024 Boston Scientific Corporation — Food and Beverage In-kind items and services $19.51 General
10/03/2024 Takeda Pharmaceuticals U.S.A., Inc. — — Cash or cash equivalent $4,880.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%)
10/01/2024 GENZYME CORPORATION ALTUVIIIO (Biological) Food and Beverage In-kind items and services $110.44 General
Category: Hematology
06/06/2024 Takeda Pharmaceuticals U.S.A., Inc. — — Cash or cash equivalent $1,220.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%)
03/01/2023 Takeda Pharmaceuticals U.S.A., Inc. — — Cash or cash equivalent $3,050.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%)
12/21/2021 Takeda Pharmaceuticals U.S.A., Inc. ADYNOVATE (Biological) — Cash or cash equivalent $3,050.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%) • Category: HEMATOLOGY
04/21/2021 Takeda Pharmaceuticals U.S.A., Inc. VONVENDI (Biological) — Cash or cash equivalent $2,745.00 Research
Study: A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) • Category: HEMATOLOGY
12/30/2020 Takeda Pharmaceuticals U.S.A., Inc. ADYNOVATE (Biological) — Cash or cash equivalent $2,440.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%) • Category: HEMATOLOGY
08/03/2020 Takeda Pharmaceuticals U.S.A., Inc. ADYNOVATE (Biological) — Cash or cash equivalent $3,050.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%) • Category: HEMATOLOGY
04/03/2020 Takeda Pharmaceuticals U.S.A., Inc. ADYNOVATE (Biological) — Cash or cash equivalent $8,540.00 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%) • Category: HEMATOLOGY
02/19/2020 Takeda Pharmaceuticals U.S.A., Inc. VONVENDI (Biological) — Cash or cash equivalent $1,830.00 Research
Study: A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) • Category: HEMATOLOGY
01/08/2020 Novartis Pharmaceuticals Corporation PROMACTA (Drug), TASIGNA Food and Beverage In-kind items and services $20.52 General
Category: ONCOLOGY
12/06/2019 Shire North American Group Inc ADYNOVATE (Biological) — Cash or cash equivalent $51.90 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 • Category: HEMATOLOGY
12/06/2019 Shire North American Group Inc ADYNOVATE (Biological) — Cash or cash equivalent $34.50 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 • Category: HEMATOLOGY
12/06/2019 Shire North American Group Inc ADYNOVATE (Biological) — Cash or cash equivalent $19.65 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 • Category: HEMATOLOGY
12/06/2019 Shire North American Group Inc ADYNOVATE (Biological) — Cash or cash equivalent $14.73 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 • Category: HEMATOLOGY
11/06/2019 Novartis Pharmaceuticals Corporation TASIGNA (Drug) Food and Beverage In-kind items and services $21.31 General
Category: HEMATOLOGY
10/20/2019 Alexion Pharmaceuticals, Inc. ULTOMIRIS (Drug) Food and Beverage In-kind items and services $48.00 General
Category: Immunology
08/07/2019 Novartis Pharmaceuticals Corporation PROMACTA (Drug), TASIGNA Food and Beverage In-kind items and services $24.38 General
Category: ONCOLOGY
05/10/2019 Shire North American Group Inc VONVENDI (Biological) — Cash or cash equivalent $2,100.00 Research
Study: A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE • Category: HEMATOLOGY
05/09/2019 Octapharma USA, Inc. NUWIQ (Biological) Food and Beverage In-kind items and services $83.50 General
Category: COAGULATION
05/01/2019 Novartis Pharmaceuticals Corporation PROMACTA (Drug), TASIGNA Food and Beverage In-kind items and services $22.20 General
Category: ONCOLOGY
02/06/2019 Novartis Pharmaceuticals Corporation TASIGNA (Drug) Food and Beverage In-kind items and services $23.06 General
Category: HEMATOLOGY
01/25/2019 Shire North American Group Inc VONVENDI (Biological) — Cash or cash equivalent $2,100.00 Research
Study: A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE • Category: HEMATOLOGY
01/21/2019 Shire North American Group Inc ADYNOVATE (Biological) — Cash or cash equivalent $3,227.40 Research
Study: PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 • Category: HEMATOLOGY
12»

Research Studies & Clinical Trials

Study Name Company Amount Records
PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII (BAX 855) IN PREVIOUSLY UNTREATED PATIENTS (PUPS) AND MINIMALLY TREATED PATIENTS (MTPS) < 6 YEARS WITH SEVERE HEMOPHILIA A (FVIII < 1%) Takeda Pharmaceuticals U.S.A., Inc. $26,230 7
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE Shire North American Group Inc $8,400 4
PHASE 3, PROSPECTIVE, MULTI-CENTER, OPEN LABEL STUDY TO INVESTIGATE SAFETY, IMMUNOGENICITY, AND HEMOSTATIC EFFICACY OF PEGYLATED FACTOR VIII BAX 855 IN PREVIOUSLY UNTREATED PATIENTS PUPS AND MINIMALLY TREATED PATIENTS MTPS 6 YEARS WITH SEVERE HEMOPHILIA A FVIII 1 Shire North American Group Inc $6,433 6
A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) Takeda Pharmaceuticals U.S.A., Inc. $4,575 2

About Dr. Deborah Brown, M.D

Dr. Deborah Brown, M.D is a Pediatrics healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083658009.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deborah Brown, M.D has received a total of $46,011 in payments from pharmaceutical and medical device companies, with $6,230 received in 2024. These payments were reported across 28 transactions from 7 companies. The most common payment nature is "" ($45,638).

Practice Information

  • Specialty Pediatrics
  • Other Specialties Pediatric Hematology-Oncology
  • Location Houston, TX
  • Active Since 06/16/2006
  • Last Updated 11/05/2020
  • Taxonomy Code 208000000X
  • Entity Type Individual
  • NPI Number 1083658009

Products in Payments

  • ADYNOVATE (Biological) $23,513
  • VONVENDI (Biological) $12,975
  • ALTUVIIIO (Biological) $110.44
  • NUWIQ (Biological) $83.50
  • PROMACTA (Drug) $67.10
  • ULTOMIRIS (Drug) $48.00
  • TASIGNA (Drug) $44.37

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatrics Doctors in Houston

Pedro Piedra, Md, MD

Pediatrics — Payments: $741,662

Pediatrics $741,662

Dr. Lisa Satter, Md, MD

Pediatrics — Payments: $255,751

Pediatrics $255,751

Hope Northrup, M.d, M.D

Pediatrics — Payments: $251,454

Pediatrics $251,454

Nidra Rodriguez, M.d, M.D

Pediatrics — Payments: $87,375

Pediatrics $87,375

Rita Swinford, M.d, M.D

Pediatrics — Payments: $75,536

Pediatrics $75,536

Bheru Gandhi, M.d, M.D

Pediatrics — Payments: $47,860

Pediatrics $47,860